Evidence map›Paper›PMID 35853881›Full record

ArticleSchizophrenia (Heidelberg, Germany)2022

Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study.

Kira Griffiths, Alice Egerton, Edward Millgate, Adriana Anton, Gareth J Barker, Bill Deakin, Richard Drake, Emma Eliasson, Catherine J Gregory, Oliver D Howes and 11 more

Open access · diamondAbstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Kira GriffithsDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.
Alice EgertonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.ORCID http://orcid.org/0000-0003-2939-064X
Edward MillgateDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.
Adriana AntonDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.ORCID http://orcid.org/0000-0002-1356-4513
Gareth J BarkerNIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-5214-7421
Bill DeakinFaculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.ORCID http://orcid.org/0000-0002-2750-962X
Richard DrakeFaculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.ORCID http://orcid.org/0000-0003-0220-4835
Emma EliassonDivision of Psychiatry, University of Edinburgh, Edinburgh, EH10 5HF, UK.
Catherine J GregoryDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.
Oliver D HowesDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.
Eugenia KravaritiDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.
Stephen M LawrieDivision of Psychiatry, University of Edinburgh, Edinburgh, EH10 5HF, UK.ORCID http://orcid.org/0000-0002-2444-5675
Shôn LewisFaculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.
David J LythgoeNIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-5078-9025
Anna MurphyDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.ORCID http://orcid.org/0000-0003-4381-0532
Scott SempleBHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, EH16 4TJ, UK.
Charlotte Stockton-PowdrellDivision of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.ORCID http://orcid.org/0000-0003-3688-308X
James T R WaltersMRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK.
Stephen R WilliamsDivision of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, M13 9PL, UK.
James H MacCabeDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK. james.maccabe@kcl.ac.uk.ORCID http://orcid.org/0000-0002-6754-1018
King's College London · GBUniversity of Manchester · GBGreater Manchester Mental Health NHS Foundation Trust · GBUniversity of Edinburgh · GBCardiff University · GB

Funding

Medical Research Council G0700995Medical Research Council MC_PC_19041Medical Research Council MC_U120097115Medical Research Council MR/L010305/1Medical Research Council MR/N026063/1Medical Research Council MR/N027078/1Medical Research Council MR/V013734/1RCUK | Medical Research Council (MRC) MR/L011794/1
6 · The paper itself

Abstract

Impaired cognition is associated with lower quality of life and poor outcomes in schizophrenia. Brain glutamate may contribute to both clinical outcomes and cognition, but these relationships are not well-understood. We studied a multicentre cohort of 85 participants with non-affective psychosis using proton magnetic resonance spectroscopy. Glutamate neurometabolites were measured in the anterior cingulate cortex (ACC). Cognition was assessed using the Brief Assessment for Cognition in Schizophrenia (BACS). Patients were categorised as antipsychotic responders or non-responders based on treatment history and current symptom severity. Inverted U-shaped associations between glutamate or Glx (glutamate + glutamine) with BACS subscale and total scores were examined with regression analyses. We then tested for an interaction effect of the antipsychotic response group on the relationship between glutamate and cognition. ACC glutamate and Glx had a positive linear association with verbal memory after adjusting for age, sex and chlorpromazine equivalent dose (glutamate, β = 3.73, 95% CI = 1.26-6.20, P = 0.004; Glx, β = 3.38, 95% CI = 0.84-5.91, P = 0.01). This association did not differ between good and poor antipsychotic response groups. ACC glutamate was also positively associated with total BACS score (β = 3.12, 95% CI = 0.01-6.23, P = 0.046), but this was not significant after controlling for antipsychotic dose. Lower glutamatergic metabolites in the ACC were associated with worse verbal memory, and this relationship was independent of antipsychotic response. Further research on relationships between glutamate and cognition in antipsychotic responsive and non-responsive illness could aid the stratification of patient groups for targeted treatment interventions.

Identifiers

PMID35853881
PMCPMC9279335
OpenAlexW4285089507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.